--- title: "BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)" type: "News" locale: "en" url: "https://longbridge.com/en/news/285817937.md" description: "BioCryst Pharmaceuticals, Inc. unveiled that the compensation committee of their board of directors provided six newly recruited employees with restricted stock units (RSUs) encompassing a total of 61,750 shares of BioCryst common stock. These RSUs were granted on May 1, 2026, to entice the employees joining the company. The grant aligns with Nasdaq Listing Rule 5635(c)(4)." datetime: "2026-05-09T16:26:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285817937.md) - [en](https://longbridge.com/en/news/285817937.md) - [zh-HK](https://longbridge.com/zh-HK/news/285817937.md) --- # BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BioCryst Pharmaceuticals, Inc. unveiled that the compensation committee of their board of directors provided six newly recruited employees with restricted stock units (RSUs) encompassing a total of 61,750 shares of BioCryst common stock. These RSUs were granted on May 1, 2026, to entice the employees joining the company. The grant aligns with Nasdaq Listing Rule 5635(c)(4). ### Related Stocks - [BCRX.US](https://longbridge.com/en/quote/BCRX.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) ## Related News & Research - [](https://longbridge.com/en/news/286807703.md) - [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md) - [Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety](https://longbridge.com/en/news/286404245.md) - [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md) - [Zydus buys US specialty drugmaker Assertio in Rs 1,600 crore all-cash deal](https://longbridge.com/en/news/286352725.md)